Product Description
Artificial Intelligence (AI) has evolved significantly. In healthcare delivery, it already enhances various aspects ranging from patient triage, diagnostics, monitoring, treatment adherence, and more. With the recent the hype around GenAI tools like ChatGPT, AI has boosted its momentum in the sector.
The pharmaceutical sector is also witnessing a surge in the adoption of new AI technologies across various facets. Reacting to the recent hype around AI and GenAI, major pharma companies have not only embraced AI with multiple internal projects, but have been actively seeking partnerships for AI, establishing a trend that reshapes the industry’s technological landscape.
In “The Pharma’s Rush into Artificial Intelligence (AI)” whitepaper, we navigate through:
- The surge in AI collaborations in the pharma industry
- The 8 use cases of AI solutions in the pharma operations
- The AI collaborations from 10 big pharma companies (BMS, Bayer, AstraZeneca, Sanofi, Pfizer, Boehringer Ingelheim, Eli Lilly, Janssen, Roche, and GSK) since 2021
- R2G’s AI partner selection and integration framework for the pharma with the help of R2GConnect global digital health and technology scouting platform
Explore which AI use cases have been targeted by the partnerships of 10 big pharma companies, who is the most active pharma company with the most AI collaborations, who are the preferred AI partners of the pharma giants, and R2G’s approach to build a growing and successful AI partnership ecosystem.
R2G has been constantly monitoring the global digital health industry since 2010. We provide strategic advice for how to build and grow a successful digital health business within all therapeutic areas, business models and regions. We are happy to talk and share our experience!
If you can’t download any of the whitepapers please write to [email protected]! Please check all your email folders, including promotion, spam, social. Thank you